{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:56:09Z","timestamp":1776135369065,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.seizure.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,8,20]],"date-time":"2017-08-20T10:46:02Z","timestamp":1503225962000},"page":"145-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anti epileptic drug trials for patients with drug resistant idiopathic generalised epilepsy: A meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"given":"Niamh","family":"Colleran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"O Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Jordan","family":"O Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2017.08.007_bib0005","series-title":"The treatment of epilepsy","author":"Shorvon","year":"2004"},{"key":"10.1016\/j.seizure.2017.08.007_bib0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1528-1167.2009.02417.x","article-title":"Examining the prevalence of epilepsy and delivery of epilepsy care in Ireland","volume":"51","author":"Linehan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0015","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2017.08.007_bib0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2017.08.007_bib0030","first-page":"157","article-title":"Management of drug\u2212resistant epilepsy","volume":"22","author":"Nair","year":"2016","journal-title":"Continum Journal"},{"key":"10.1016\/j.seizure.2017.08.007_bib0035","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1528-1167.2011.03041.x","article-title":"The etiology class epilepsy","volume":"52","author":"Shovron","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0040","first-page":"117","article-title":"Idiopathic (primary) generalised epilepsy","volume":"18","author":"Yadegari","year":"2013","journal-title":"Neurosciences"},{"key":"10.1016\/j.seizure.2017.08.007_bib0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1528-1167.2010.02542.x","article-title":"The new ILAE classification","volume":"51","author":"Shinnar","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0050","first-page":"2128","article-title":"Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors","volume":"81","author":"Senf","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(00)00210-2","article-title":"Idiopathic generalised epilepsies with pure grand mal: clinical data and genetics","volume":"44","author":"Unterberger","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.08.007_bib0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2011.10.009","article-title":"Physical injuries in patients with epilepsy and their associated risk factors","volume":"21","author":"Asadi-Pooya","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2017.08.007_bib0065","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1474-4422(13)70214-X","article-title":"Incidence and mechanisms of respiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study","volume":"12","author":"Ryvlin","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2017.08.007_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-1211(02)00065-7","article-title":"The clinical impact of new antiepileptic drugs after a decade of use in epilepsy","volume":"50","author":"Schmidt","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.08.007_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1212\/WNL.32.2.157","article-title":"Valproic acid versus ethosuximide in the treatment of absence seizures","volume":"32","author":"Sato","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0080","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassified epilepsy: an unblended randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2017.08.007_bib0085","unstructured":"NICE. Epilepsies: diagnosis and management NICE guidelines (CG137), 2012. https:\/\/www.nice.org.uk\/guidance\/cg137 Accessed February 2016."},{"key":"10.1016\/j.seizure.2017.08.007_bib0090","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jocn.2004.05.003","article-title":"Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy","volume":"11","author":"Vajda","year":"2004","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.seizure.2017.08.007_bib0095","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo\u2212controlled study of levetiracetam in idiopathic generalised epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0100","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic clonic seizures","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0105","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","article-title":"Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures","volume":"65","author":"Biton","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.yebeh.2010.07.022","article-title":"Adjunctive lamotrigine XR for primary generalised tonic\u2013clonic seizures in a randomised, placebo-controlled study","volume":"19","author":"Biton","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2017.08.007_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic clonic seizures in idiopathic generalised epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0120","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1542\/peds.2006-0148","article-title":"Lamotrigine adjunctive therapy among children and adolescents with primary generalised tonic clonic seizures","volume":"118","author":"Trevathan","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.seizure.2017.08.007_bib0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/adc.2004.058222","article-title":"Understanding randomised controlled trials","volume":"90","author":"Akobeng","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.seizure.2017.08.007_bib0130","unstructured":"The Cochrane Collaboration. RevMan 5.3 Tool (Online), 2013. Available at: http:\/\/tech.cochrane.org\/revman (Accessed 17, March 2016)."},{"key":"10.1016\/j.seizure.2017.08.007_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2017.08.007_bib0140","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1528-1157.1997.tb04518.x","article-title":"Preliminary open label experience with topiramate in primary generalised seizures","volume":"38","author":"Biton","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-1211(96)00020-4","article-title":"Gabapentin in generalised seizures","volume":"25","author":"Chadwick","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.08.007_bib0150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0155","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1528-1157.1998.tb01332.x","article-title":"Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy","volume":"39","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a Randomized, Double-Blind, Crossover Study","volume":"39","author":"Eriksson","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy aoutcomes at 12 months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0170","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1528-1167.2010.02976.x","article-title":"A multicentre, randomised, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy","volume":"52","author":"Fattore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0175","series-title":"Systematic reviews to support evidence-based medicine: how to apply findings of healthcare research","author":"Khan","year":"2004"},{"key":"10.1016\/j.seizure.2017.08.007_bib0180","first-page":"635","article-title":"Interpreting and understanding meta-analysis graphs: a practical guide","volume":"35","author":"Ried","year":"2006","journal-title":"Aust Fam Phys"},{"key":"10.1016\/j.seizure.2017.08.007_bib0185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","article-title":"Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose response analysis of phase III studies","volume":"55","author":"Kramer","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0190","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"6","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.08.007_bib0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.08.007_bib0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.08.007_bib0205","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131116303168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131116303168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:49:12Z","timestamp":1761011352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131116303168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":41,"alternative-id":["S1059131116303168"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2017.08.007","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti epileptic drug trials for patients with drug resistant idiopathic generalised epilepsy: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}